Ottawa Mariott, Ottawa, Canada
Nov 6 2012 7:00AM - Nov 7 2012 4:00PM
Rethinking and Redesigning Traditional Approaches during Changes in the Industry Benefit-risk considerations are a central concept to the development, authorization and marketing of health products. As the industry undergoes a period of unprecedented change, traditional approaches to drug development are being re-designed. As our way of thinking about and managing risk also evolves, and as we seek to optimize patient outcomes and minimize risk, this meeting will explore the challenges that industry, regulators, policy makers and those involved in health product lifecycle face in understanding and defining acceptable levels of risk across disciplines and through the drug development and lifecycle management. This conference will challenge participants to explore how our thinking about benefit-risk management has and continues to evolve. The DIA’s Annual Canadian Meeting: Evolutions in Risk Thinking features: • Preconference tutorials • Cross-functional sessions dedicated to the different areas of interest • Networking opportunities (reception, interaction with regulators, cross-disciplinary networking) • Question and answer sessions • Case studies • Presentation of best practices • Table top exhibits Benefits of DIA’s Annual Canadian Meeting: Evolutions in Risk Thinking: • Leave with solutions for development strategy • Meet colleagues from business partner functions to discuss new ideas • Look at a particular operations topic from different angles • Network with professional colleagues • Interact with speakers from the industry and regulatory agencies • Enhance awareness of scientific areas Event Code: 12019
|